USD 5.2 billion
Report ID:
SQMIG35H2300 |
Region:
Global |
Published Date: November, 2024
Pages:
197
|Tables:
95
|Figures:
73
Global CAR T-Cell Therapy Market size was valued at USD 5.2 billion in 2022 and is poised to grow from USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031).
Rising incidence of cancer around the world is projected to primarily augment the demand for CAR T-cell therapy (CAR-T (Chimeric Antigen Receptor T-cell) therapy) over the coming years. Rising investments in cell research and advancements in genetic engineering and editing technologies are also expected to play a crucial role in CAR T-cell therapy market development over the coming years. High demand for personalized medicine is also estimated to uplift the demand for CAR T-cell therapy across the forecast period and beyond. Growing use of CAR T-cell therapy to treat blood cancer indications is also expected to create new opportunities for CAR T-cell therapy providers in the future. Increasing number of approvals for novel CAR T-cell therapy for the treatment of various chronic indications that are rising in incidence on a global level. On the contrary, high costs of treatment, concerns regarding safety of the procedure and side effects, and limited availability are estimated to be key restraints for CAR T-cell therapy market over the coming years.
Global Market Size
USD 5.2 billion
Largest Segment
Hospitals
Fastest Growth
Adults
Growth Rate
39.80%
To get more reports on the above market click here to Buy The Report
Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Demographic, End User, and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other Products. Based on Target, the market is segmented into CD19, BCMA, and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Other Indications. Based on Demographic, the market is segmented into Adults, and Pediatrics. Based on End User, the market is segmented into Hospitals, Specialty Centers, and Long-Term Care Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Disease Indication
Use of CAR T-cell therapy is projected to be the highest for the treatment of lymphoma around the world. Growing incidence of lymphoma and rising availability of novel CAR T-cell therapy candidates for the treatment of the same are estimated to help the dominance of this segment. Rising prevalence of B-cell lymphoma among adults as well as children is also projected to promote the demand for CAR T-cell therapy and CAR T drugs as well in the future. Surging awareness regarding efficacy of CAR T-cell therapy against lymphoma will also contribute to the high market share.
Meanwhile, the use of CAR T-cell therapy for the treatment of multiple myeloma is forecasted to increase at a robust pace across the study period and beyond. Rapidly increasing aging population around the world is a major contributor to the rising incidence of multiple myeloma. Growing awareness regarding the efficacy of CAR T-cell therapy to treat multiple myeloma and rising demand for better treatment for this indication are also expected to create new opportunities for CAR T-cell therapy companies going forward.
Analysis by End User
Hospitals are projected to account for a dominant share of the global CAR T-cell therapy market. Growing acceptance of novel therapies among patients and the rising availability of CAR T-cell therapy in hospitals are primarily contributing to the dominance of this segment. Increasing investments in healthcare infrastructure development and in-house hospital facilities contributing to reducing costs of CAR T-cell therapy for patients are also anticipated to create new business opportunities going forward.
Rapid surge in cancer incidence around the world is projected to bolster the demand for CAR T-cell therapy in cancer care centers at a rapid pace over the coming years. Rising acceptance and use of CAR T-cell therapy for the treatment of cancer and growing willingness of cancer patients to spend on CAR T-cell therapy are all helping this segment boost market growth in the future.
To get detailed analysis on other segments, Request For Free Sample Report
North America is projected to account for a dominant share of the global CAR T-cell therapy market. High investments in medical R&D and rising acceptance of cell therapies among patients are projected to help the high market share of this region. The United States is estimated to be the most opportune market for CAR T-cell therapy companies owing to the presence of key CAR T-cell therapy providers. High healthcare spending potential and rising availability of reimbursement of CAR T-cell therapies will also create new opportunities for CAR T-cell therapy providers in the future.
The Asia Pacific region is expected to emerge as the fastest-expanding market for CAR T-cell therapies in the world going forward. Rapidly increasing patient population, growing spending on healthcare, and rising demand for novel treatments are estimated to bolster the demand for CAR T-cell therapy in this region. China, Japan, and India are anticipated to emerge as the most opportune markets for all CAR T-cell therapy companies in the world. Presence of multiple contract research organizations and easy regulatory approval procedures will also play a crucial role in promoting the demand for CAR T-cell therapy in the Asia Pacific region over the coming years.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Demand for Personalized Medicine
Rising Investments Cell Research
Reseach on cells has come a long way owing to robust investments from the public and private sectors around the world. This has resulted in significant advancements in cell research, which are being applied in the development of advanced CAR T-cell therapy thereby creating new business opportunities as well.
Restraints
Risk of Side Effects and Safety Concerns
High Costs of Treatment
Request Free Customization of this report to help us to meet your business objectives.
CAR T-cell therapy companies should focus on research to improve efficacy of their offerings and make them more affordable as well. CAR T-cell therapy companies should also focus on providing CAR T-cell therapies for a wide variety of diseases to maximize their business scope in the long run. Partnerships, government grants, and mergers are some key aspects that will play a crucial role in success of any CAR T-cell therapy company going forward.
Top Player’s Company Profiles
Recent Developments
CAR T-cell therapy companies can invest in the development of allogeneic therapies to eliminate the need for patient-specific manufacturing of cells and improve accessibility and affordability of CAR T-cell therapy. This move will help CAR T-cell therapy providers expand their business scope in the long run and improve chances of success in emerging markets.
CAR T-cell therapy providers can focus on improving their research and operations by integrating advanced technologies such as artificial intelligence and machine learning to automate different tasks. This could help reduce costs of R&D and also fast-track development of novel CAR T-cell therapy.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, high investments in medical R&D and growing demand for advanced cell therapies for various chronic diseases are projected to bolster CAR T-cell therapy market growth in the future. However, the risk of side effects and high costs of treatment are projected to inhibit CAR T-cell therapy demand outlook in the long run. Demand for CAR T-cell therapy in the Asia Pacific region is slated to increase at a rapid pace across the forecast period owing to increasing patient pool and increasing incidence of cancer. Developing allogeneic CAR T-cell therapy will be a key opportunity for new as well as established CAR T-cell therapy providers going forward.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 5.2 billion |
Market size value in 2031 | USD 106.06 billion |
Growth Rate | 39.80% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the CAR T-Cell Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the CAR T-Cell Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the CAR T-Cell Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the CAR T-Cell Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2300
sales@skyquestt.com
USA +1 351-333-4748